OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocula…
$1.43+2.14%
报价 2026-11-06
市值
$75M
EV
$66.2M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -54.0%
$1.29$3.11
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| OKYOOKYO Pharma Limited | $75M | +2.1% | – | 0% | – | – | – | |
| IMDXInsight Molecular Diagnostics Inc. | $81.5M | +1.2% | -18.8% | 11.2% | – | – | – | |
| TNXPTonix Pharmaceuticals Holding Corp. | $81.3M | +3.0% | +189.4% | 52.6% | – | – | – | |
| ATRAAtara Biotherapeutics, Inc. | $79M | -1.1% | -86.5% | 91.4% | – | – | – | |
| NRXSNeurAxis, Inc. | $78.4M | +2.1% | +174.3% | 85.6% | – | – | – | |
| ADAGAdagene Inc. | $75.3M | -1.0% | – | 94.2% | – | – | – | |
| MNOVMediciNova, Inc. | $71.9M | +0.7% | +100.0% | 42.4% | – | – | – | |
| COYACoya Therapeutics, Inc. | $70.1M | +6.4% | -61.0% | 99.8% | – | – | – | |
| ACRVAcrivon Therapeutics, Inc. Common Stock | $69M | +2.5% | +1400.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +100.0% | 69.1% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。